✦ LIBER ✦

0148 REACT study: A phase III multicentre double blind randomised trial of celecoxib versus placebo in primary breast cancer patients

✍ Scribed by G. von Minckwitz; B. Conrad; C. Denkert; H. Eidtmann; W. Eiermann; W. Harbeck; J. Huober; C. Jackisch; H. Lück; V. Möbus; T. Reimer; A. Rody; E. Stickeler

Book ID: 114316285
Publisher: Elsevier Science
Year: 2009
Tongue: English
Weight: 57 KB
Volume: 18
Category: Article
ISSN: 0960-9776
DOI: 10.1016/s0960-9776(09)70179-1

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Celecoxib and exemestane versus placebo

Celecoxib and exemestane versus placebo and exemestane in postmenopausal metastatic breast cancer patients: a double-blind phase III GINECO study

✍ C. Falandry; M. Debled; T. Bachelot; T. Delozier; J. Crétin; P. Romestaing; D. M 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 239 KB

A randomised double-blind controlled tri

A randomised double-blind controlled trial of oral soy supplements versus placebo for treatment of menopausal symptoms in patients with early breast cancer

✍ C.A. MacGregor; P.A. Canney; G. Patterson; R. McDonald; J. Paul 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 127 KB

Golimumab in patients with active rheuma

Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor α inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial

✍ Josef S Smolen; Jonathan Kay; Mittie K Doyle; Robert Landewé; Eric L Matteson; J 📂 Article 📅 2009 🏛 The Lancet 🌐 English ⚖ 222 KB

Effect of celecoxib on survival in patie

Effect of celecoxib on survival in patients with advanced non-small cell lung cancer: A double blind randomised clinical phase III trial (CYCLUS study) by the Swedish Lung Cancer Study Group

✍ Andrea Koch; Bengt Bergman; Erik Holmberg; Christer Sederholm; Lars Ek; Jaroslaw 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 504 KB

Preoperative gefitinib versus gefitinib

Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial

✍ Andreas Polychronis; H Dudley Sinnett; Dimitri Hadjiminas; Hemant Singhal; Janin 📂 Article 📅 2005 🏛 The Lancet 🌐 English ⚖ 244 KB

Gefitinib versus placebo as maintenance

Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer (INFORM; C-TONG 0804): a multicentre, double-blind randomised phase 3 trial

✍ Li Zhang; Shenglin Ma; Xiangqun Song; Baohui Han; Ying Cheng; Cheng Huang; Shuju 📂 Article 📅 2012 🏛 The Lancet 🌐 English ⚖ 371 KB